Login to Your Account

Financings Roundup

MAP Seeks $52M, Prepares to Resubmit Levadex NDA

By Marie Powers
Staff Writer

Thursday, August 2, 2012

MAP Pharmaceuticals Inc. priced an underwritten public offering of 3.9 million shares of its common stock at $13.40 apiece, seeking to raise $52 million as the biotech prepares to resubmit the new drug application (NDA) for Levadex, its inhalation aerosol for the acute treatment of migraine.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription